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Abstract
Natural killer (NK) cell-based adoptive immunotherapy is an attractive adjuvant treatment option for patients with acute
myeloid leukemia. Recently, we reported a clinical-grade, cytokine-based culture method for the generation of NK cells from
umbilical cord blood (UCB) CD34+ hematopoietic progenitor cells with high yield, purity and in vitro functionality. The
present study was designed to evaluate the in vivo anti-leukemic potential of UCB-NK cells generated with our GMP-
compliant culture system in terms of biodistribution, survival and cytolytic activity following adoptive transfer in
immunodeficient NOD/SCID/IL2Rgnull mice. Using single photon emission computed tomography, we first demonstrated
active migration of UCB-NK cells to bone marrow, spleen and liver within 24 h after infusion. Analysis of the chemokine
receptor expression profile of UCB-NK cells matched in vivo findings. Particularly, a firm proportion of UCB-NK cells
functionally expressed CXCR4, what could trigger BM homing in response to its ligand CXCL12. In addition, high expression
of CXCR3 and CCR6 supported the capacity of UCB-NK cells to migrate to inflamed tissues via the CXCR3/CXCL10-11 and
CCR6/CCL20 axis. Thereafter, we showed that low dose IL-15 mediates efficient survival, expansion and maturation of UCB-
NK cells in vivo. Most importantly, we demonstrate that a single UCB-NK cell infusion combined with supportive IL-15
administration efficiently inhibited growth of human leukemia cells implanted in the femur of mice, resulting in significant
prolongation of mice survival. These preclinical studies strongly support the therapeutic potential of ex vivo-generated UCB-
NK cells in the treatment of myeloid leukemia after immunosuppressive chemotherapy.
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Introduction
Acute myeloid leukemia (AML) is a clonal disorder character-
ized by the accumulation of abnormal myeloid progenitor cells
and suppression of normal hematopoiesis [1]. With a median age
of ,70 years at diagnosis [2], AML is most common in the elderly
and its yearly incidence is expected to increase as the population
ages [3]. Current chemotherapeutic regimens lead to remission
rates of 60–85%. However, relapse occurs in the vast majority of
AML cases, resulting in a 5-year overall survival of 40% in patients
,60 years of age, which even drops to 10% in elderly patients due
the higher prevalence of bad risk cytogenetics and poor
chemotherapeutic tolerance [4]. Although allogeneic stem cell
transplantation (alloSCT) is potentially curative, mostly younger
patients can benefit from this therapeutic option due to high
association with transplant-related morbidity and mortality [5].
Therefore, adjuvant and alternative treatment options are urgently
needed.
Transfusion of allogeneic NK cells is a promising therapeutic
approach for patients with AML. NK cells are major effector cells
of the innate immune system and play a key role in control against
virus infection and tumor immunosurveillance [6,7]. In the setting
of haploidentical alloSCT, NK cell alloreactivity has proven to
decrease relapse rate and improve survival among AML patients
[8]. Therefore, there is an emerging interest in exploiting adoptive
NK cell transfer in the treatment of AML. Clinical studies
reported so far showed that infusion of haploidentical NK cells
derived from leukapheresis products resulted in objective clinical
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responses in high-risk AML patients [9,10], as well as long term
remissions in childhood AML [11].
However, further improvement of NK cell-based therapy is
needed to increase the clinical effect. In this regard, NK cells
generated ex vivo from hematopoietic progenitor cells (HPC) may
have significant clinical benefits over enriched NK cells from adult
donors, including the ability to choose an appropriate killer-cell
immunoglobulin-like receptor (KIR)-ligand or KIR B haplotype
alloreactive donor, as well as the capacity to reach high
therapeutic dosages. Recently, we reported a GMP-compliant,
cytokine/heparin-based culture protocol for the ex vivo generation
of highly active NK cells from CD34+ HPC isolated from
cryopreserved umbilical cord blood (UCB) units [12]. Expansion
in closed, large-scale bioreactors yields a clinically relevant dose of
NK cells with high purity and cytolytic activity against AML cells
in vitro [13].
In the present study, we aimed at evaluating the anti-leukemic
potential of UCB-NK cells in vivo in terms of biodistribution,
survival and cytotoxicity following adoptive transfer in NOD/
SCID/IL2Rgnull (NSG) mice. Therefore, we established an
111Indium labelling protocol that enables specific and sensitive
in vivo tracking of infused UCB-NK cells by single photon emission
computed tomography (SPECT) imaging. Besides generating
insight in UCB-NK cell trafficking, we demonstrated specific
accumulation of UCB-NK cells in the bone marrow (BM) that
matched their chemokine receptor profile. Moreover, we demon-
strated that a single infusion of UCB-NK cells resulted in potent
leukemia cell growth inhibition and significantly improved mice
survival. These findings strongly support ex vivo-generated UCB-
NK cells as promising immunotherapeutic products for the
treatment of AML.
Materials and Methods
UCB-NK Cell Generation
UCB units were obtained at birth after normal full-term
delivery after written informed consent with regard of scientific use
from the cord blood bank of the Radboud University Nijmegen
Medical Centre (RUNMC, Nijmegen, The Netherlands). The use
of UCB units was approved by the RUNMC Institutional Review
board. NK cells were generated from cryopreserved UCB-derived
HPC as previously reported [12,13]. Briefly, expanded CD34+
UCB cells were differentiated and further expanded using NK cell
differentiation medium which consists of Glycostem Basal Growth
Medium (GBGMH) for cord blood (Clear Cell Technologies)
supplemented with 2% human serum (HS; Sanquin Blood Supply
Foundation, Nijmegen, The Netherlands), low-dose GM-CSF
(Neupogen), G-CSF, IL-6 (both CellGenix) and a high-dose
cytokine cocktail consisting of IL-7, SCF, IL-15 (all CellGenix) and
IL-2 (ProleukinH). The cell density was checked two times a week
and adjusted to .16106 cells/ml by the addition of GBGMH NK
cell differentiation medium. For experiments, CD56+CD32 UCB-
NK cells were used at the end of the culture process with .90%
purity, what was typically achieved within 3–4 weeks in GBGMH
NK cell differentiation medium.
Flow Cytometry
Cell numbers and expression of cell surface markers were
determined by flow cytometry. Anti-human CD45-ECD (J.33) and
CD56-PC7 (N901) antibodies (Beckman Coulter) were used to
follow cell number and NK cell differentiation during culture
using the Coulter FC500 flow cytometer (Beckman Coulter). The
population of living CD45+ cells was determined by exclusion of
7AAD (Sigma) positive cells. For phenotypical analysis, UCB-NK
cells were incubated with the appropriate concentration of
antibodies for 30 min at 4uC. After washing, cells were
resuspended in PBS/0.5% BSA and analyzed using the Coulter
FC500 or Cyan-ADP 9 color flow cytometers (Beckman Coulter).
The following conjugated monoclonal antibodies were used:
CCR2 (48607, R&D system), CCR5 (T21/8, eBioscience),
CCR6 (TG7), CCR7 (G043H7), CXCR3 (G025H7), CXCR4
(12G5), CXCR6 (TG3), CX3CR1 (2A9–1) and CD62L (DREG-
56, all Biolegend).
In vitro Cell Migration Assay
UCB-NK cells were resuspended in GBGM/2% HS and
loaded into transwell inserts (105 cells/well, 5 mm pore filter
transwell, 24-well plate, Corning). The human chemokines CCL4,
CCL20, CXCL10, CXCL11 and CXCL12 (all Immunotools)
were diluted at 10–250 ng/ml and added to the lower compart-
ment (600 ml/well) in triplicates. After 2 h at 37uC, inserts were
removed; cells in lower compartments were collected, stained for
CD56 and quantified by flow cytometry. Percentage of migrated
cells was calculated as the number of CD56+ cells in the lower
compartment divided by the total number of CD56+ loaded cells.
Mice
NOD/SCID/IL2Rgnull (NSG) mice were originally purchased
from Jackson Laboratories, and housed and bred in the RUNMC
Central Animal Laboratory. Male NSG mice were used from 6 to
12 weeks of age (weight was 20–30 g). All animal experiments
were approved by the Animal Experimental Committee of the
RUNMC and were conducted in accordance with institutional
and national guidelines under the university permit number
10300.
NK Cell Labeling with 111Indium, SPECT-CT Imaging and
Biodistribution Analysis
UCB-NK cells were labeled with 111Indium-oxinate (111In; GE
Healthcare) in PBS Tris 0.1 M HCl, pH 7.4 for 15 min at RT at
doses mentioned in the text. After incubation, cells were washed
twice with PBS/2% HS and resuspended in PBS before use.
Viability was assessed by trypan blue exclusion and cell-associated
activity was quantified using a dose calibrator VDC-404 (Veenstra
Instruments, The Netherlands). Lysates were obtained after three
freezing/thawing cycles of 111In-NK cells previously resuspended
in distilled water. Whole body scans of isoflurane gas anesthetized
(2% in air) mice were acquired with a SPECT-CT dual-modality
scanner (U-SPECT II, MiLabs) for 30–45 min using a 1.0 mm
diameter pinhole mouse collimator cylinder. Scans were recon-
structed with MiLabs reconstruction software and analyzed using
Inveon Research Workplace software. For biodistribution analysis,
mice were euthanized by cervical dislocation, tissues of interest
were dissected, weighed, and analyzed for their 111In content using
a shielded 3-inch-well-type gamma counter (Wizard; Pharmacia
LKB). The 111In activity in each tissue was expressed as
percentage of the injected dose (%ID) per gram of tissue and
was normalized to the blood level. Values for the total blood and
BM fraction were extrapolated according to physiological values,
with blood being 6% of the total body weight, and one femur
being 6.7% of the total BM fraction [14].
Intra-femoral K562 Model, Bioluminescence Imaging and
UCB-NK Cell Adoptive Transfer
The NK-sensitive leukemia cell line K562 (ATCC) was cultured
in Iscove’s modified Dulbecco’s medium (IMDM; Invitrogen)
containing 50 U/ml penicillin, 50 mg/ml streptomycin and 10%
HSC-Derived NK Cells for AML Immunotherapy
PLOS ONE | www.plosone.org 2 June 2013 | Volume 8 | Issue 6 | e64384
fetal calf serum. Green fluorescent protein (GFP) and Luciferase
expressing K562 cells (K562.LucGFP) were generated by stable
transduction of parental cells with lentiviral particles LVP20
encoding the reporter genes under control of the CMV promoter
(GenTech). To establish a preclinical AML xenograft model, adult
NSG mice were injected in their right femur with 105
K562.GFPLuc cells (injection volume= 5 ml), by insertion of a
25G Hamilton needle through the knee joint of isoflurane gas
anesthetized mice. Using this procedure, leukemia cell growth
remained localized to BM up to 5 weeks. Thereafter, tumor cells
eventually overgrow outside the bone forming a palpable tumor.
Mice were sacrificed (cervical dislocation) when the palpable
tumor reached 1 cm in diameter or when one of the following
criteria was observed: severe weight loss, poor coat and skin
condition, static activity or paraplegia. Leukemia load was
monitored by bioluminescence imaging (BLI) following injection
of Luciferine (3.5 mg per mouse, Caliper Life Science) using the
IVIS system (Xenogen). Images were analyzed using Living Image
Software 2.5 (Xenogen). Leukemia load was quantified in the
region of interest with subtraction of background signal, and
expressed as photons per second. For adoptive transfer, UCB-NK
cells were resuspended in PBS and injected i.v. via the tail vein of
Figure 1. Homing receptor expression profile of UCB-NK cells. (A–B) The expression level of homing receptors was analysed by flow
cytometry on UCB-NK cells at the end of the culture process. (A) Dot plots gated on CD56+ cells from one representative donor; (B) Summary of 6
different donors analysed. (C) The capacity of UCB-NK cells to respond in vitro to gradients (10 to 250 ng/ml) of the chemokines CCL4 (CCR5 ligand),
CCL20 (CCR6 ligand), CXCL10, CXCL11 (both CXCR3 ligand) and CXCL12 (CXCR4 ligand) was evaluated in transwell migration assays as described in
materials and methods. Mean 6 SEM of three independent experiments are shown, each performed with different UCB-NK cell donors. Migration
towards specific chemokines was compared to non-specific migration (0 ng/ml) using a one way-ANOVA followed by Dunnett’s multiple comparison
post-hoc test, *p,0.05, **p,0.01, ***p,0.001.
doi:10.1371/journal.pone.0064384.g001
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adult NSG mice. Recombinant human IL-15 (Miltenyi Biotech)
was administrated intra-peritoneally (i.p.) at the dose of 0.5 mg/
mouse (i.e. 2.500 Units/mouse) the day of UCB-NK cell infusion
and thereafter every 2–3 days for 2 weeks.
Statistical Analysis
Statistical analyses were performed using Graphpad Prism 5
software. Biodistribution of 111In-associated activity following
111In-NK cell infusion was compared to that observed after lysate
or free 111In injection using one way-analysis of variance
(ANOVA) and Dunnett’s multiple comparison tests. Two way-
ANOVA followed by Bonferroni post-hoc test, and log rank
Mantel Cox tests were used in anti-leukemic studies as indicated in
the figure legends. Differences were considered to be significant for
p values ,0.05.
Results
Characterization of the Homing Receptor Expression
Profile of UCB-NK Cells
We reported previously that the cytokine-based culture system
that we established allows generation of CD32CD56+ NK cells
with high purity, that express typical inhibitory and activating NK
receptors and display similar cytotoxic gene expression profile to
peripheral blood NK cells [15]. To further characterize UCB-NK
cell products and to investigate their biodistribution potential upon
Figure 2. SPECT-CT imaging provides good sensitivity and specificity to track 111In-labeled UCB-NK cells in vivo. To address the
feasibility of UCB-NK cell tracking in vivo, adult NSG mice were injected i.v. either with increasing doses of 111In-NK cells (1, 5 or 126106 111In-NK cells
per mouse equivalent to 1, 5 and 12 MBq respectively, n = 5 in total), with a lysate obtained from 111In-NK cells (111In-lysate, n = 2) or with 111In-
oxinate (n = 3). (A) Representative whole body SPECT scans acquired 1 h and 24 h after injection of 111In-NK cells with major visualization of lungs
(Lu), liver (Li), spleen (Sp, arrowhead) and bone marrow (BM, arrow). (B) Representative whole body SPECT scans acquired 24 h after injection of 111In-
NK cell lysate or 111In-oxinate; kidneys (Ki), heart (He). (C) Quantitative biodistribution analysis performed 24 h after injection. For comparison, the
relative 111In-content of each tissue of interest was normalized to blood. Data are shown as mean 6 SD. *p,0.05, **p,0.01, ***p,0.001.
doi:10.1371/journal.pone.0064384.g002
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adoptive transfer, we examined the expression and functionality of
a panel of receptors that were previously described to participate
in the regulation of human NK cell trafficking in vivo [16,17]. As
shown in Figure 1A–B, the chemokine receptors CCR2, CCR5,
CCR7, CXCR6 and CX3CR1 were virtually absent. However,
high proportion of UCB-NK cells expressed CCR6 (52612%) and
CXCR3 (65621%). Expression of CXCR4 as well as the adhesion
molecule CD62L (L-selectin) were also detected typically on 10–
20% of UCB-NK cells at the end of the culture process. Results
obtained from in vitro migration assays were consistent with this
chemokine receptor profile (Figure 1C). Notably, the proportion of
CD56+ UCB-NK cells migrating in response to the chemokine
CXCL12 was similar to level of CXCR4-expressing cells, and
specific migration towards the chemokines CCL20 (CCR6 ligand),
CXCL10 and CXCL11 (both CXCR3 ligands) were confirmed.
These data indicate that UCB-NK cells functionally express
CXCR4, what could trigger BM homing in response to its ligand
CXCL12. In addition, data suggest that UCB-NK cells have the
capacity to migrate to inflamed tissues via the CXCR3/CXCL10–
11 and CCR6/CCL20 axis.
Development of in vivo UCB-NK Cell Tracking
Next, we aimed to establish a method using 111In-oxinate as
radiolabel and SPECT-CT imaging that could be exploited both
at the pre-clinical level in mice and for clinical studies in humans,
to monitor early distribution of UCB-NK cell following infusion in
relation to anti-leukemic potency in BM. To address the feasibility
of this methodology, increasing doses of UCB-NK cells previously
labeled with 111In-oxinate (111In-NK cells; 2MBq of 111In-oxinate
was added per 106 cells and labeling efficiency was 55%) were
injected i.v. into NSG mice. Whole body scans acquired 1 and
24 h after infusion showed that the 111In-activity first localized in
the lungs, and thereafter redistributed to the spleen, liver and BM
(Figure 2A). At 24 h, liver and spleen were visible at all doses of
infused 111In-NK cells, while the activity present in BM was
detected only in mice injected with $56106 111In-NK cells. To
address the specificity of 111In-NK cell in vivo imaging, we also
analyzed the distribution of 111In-activity following injection of
either a lysate obtained from 111In-NK cells or 111In-oxinate
(Figure 2B). In both cases, after 24 h, the activity was mainly
visualized in kidneys. Weak uptake of 111In was noticed in liver
and lungs following injection of 111In-lysate and 111In-oxinate,
respectively.
After imaging, mice were euthanized, organs were collected,
weighted, and used to analyse quantitatively the distribution of the
111In-activity as described in materials and methods. All tissues
examined following injection of 111In-oxinate exhibited similar
level of 111In compared to that measured in blood, indicating that
the 111In activity remained in the circulation, resulting in
visualization of well perfused organs. In mice injected with
111In-lysate, the activity mainly accumulated in the kidneys,
representing ,20% of the injected dose (data not shown). Slightly
enhanced 111In activity levels were also measured in liver and
lymphoid organs. In contrast, following infusion of 111In-NK cells,
the proportions of activity quantified in BM, spleen, liver and
lungs were strongly increased compared to blood level. Values
were also significantly higher compared to those determined
following injection of 111In-lysate and 111In-oxinate (Figure 2C),
indicating that the accumulation of 111In activity in these organs
could be attributed to the accumulation of 111In-NK cells.
Notably, the distribution of 111In activity was similar at all doses
of infused 111In-NK cells (Figure S1). Moreover, human
CD45+CD56+ NK cells were clearly identified in the same organs,
except kidneys, by ex vivo flow cytometric analysis performed 24 h
after infusion of UCB-NK cells (Figure 3). All together, these data
show that SPECT-CT imaging allows tracking of 111In-NK cells
in vivo with good sensitivity and specificity, and that UCB-NK
cells, after a brief period of retention in the lungs, rapidly traffic to
the liver, spleen and BM.
A Consistent Proportion of UCB-NK Cells Accumulates in
Mouse BM Following Adoptive Transfer
After demonstrating the feasibility of 111In-NK cell tracking
in vivo, we aimed to determine quantitatively the biodistribution of
UCB-NK cells in 2 independent experiments. To this end, we first
optimized the labelling procedure by incubating increasing
numbers of NK cells with 2 MBq 111In. Good 111In labelling
efficiency and cell recovery were achieved using .46106 cells
(Figure 4A). Based on these findings, 0.4 MBq of 111In-oxinate was
added per 106 cells for subsequent experiments where labeling
efficiency always exceeded 80%, cell viability .90% and cell
recovery .95% (data not shown). In addition, this procedure did
not affect the migration capacity of UCB-NK cells towards the
prototypic BM-chemokine CXCL12 in vitro (Figure 4B).
As observed in the pilot studies, we found the highest activity
concentration in the spleen, followed by liver, BM and lungs at
24 h after infusion. Taking into account total organ weights,
nearly 70% (64.962.1) of the ID was present in liver, while spleen
and lungs contained 3.161.2%ID and 3.961.9%ID, respectively
(Figure 4C). For BM, 0.3260.05%ID was quantified per femur
(data not shown). Assuming that one femur accounts for 6.7% of
the total BM in adult mouse [14], we estimated at ,5% the
fraction of 111In-NK cells accumulating within 24 h in the total
BM compartment. Accordingly, a homogenous 111In-signal was
visualized by SPECT-CT imaging in all bones (Figure 4D). These
data indicate that a significant percentage of UCB-NK cells are
able to migrate to the mouse BM following adoptive transfer.
Low Dose Human IL-15 Drives UCB-NK Cell Expansion
in vivo
Next to BM homing, we aimed to evaluate the survival potential
of UCB-NK cells following adoptive transfer. Indeed, clinical
responses reported so far always occurred with concomitant donor
NK cell persistence and even expansion within the first two weeks
after infusion. Interestingly, conditioning regimens that allowed
successful alloNK cell engraftment also resulted in transient
elevation of endogenous IL-15 [9]. Therefore, we examined UCB-
NK cell survival potential upon adoptive transfer in NSG mice in
the presence of low dose IL-15 support. In a first experiment, we
observed that daily administration of IL-15 mediated efficient
expansion of infused UCB-NK cells in vivo (Figure S2). In contrast
to mice injected with UCB-NK cells alone, a clear population of
human CD45+CD56+ cells could be visualized in mice co-injected
with IL-15, representing 3.5% of total leukocytes at day 7, which
Figure 3. Ex vivo flow cytometric analysis confirmed trafficking of UCB-NK cells through lymphoid tissues, liver and lungs following
adoptive transfer in NSG mice. Two adult NSG mice were infused i.v. with 106106 UCB-NK cells. The day after, mice were sacrificed, organs
collected and used to prepare cell suspension for ex vivo flow cytometric analysis following erythrocyte lysis. One additional non-injected mouse was
used as control. Presence of human CD45+CD56+ NK cells was confirmed in all examined tissues except kidneys. Dot plots gated on total living cells
are shown.
doi:10.1371/journal.pone.0064384.g003
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further increased till 4.5% at day 14. Nevertheless, NK cell
numbers rapidly declined after removal of IL-15 (Figure S2). We
next intended to confirm these findings with a different UCB
donor and to examine UCB-NK cell engraftment level in
lymphoid tissues. To this end, mice received a single infusion of
56106 UCB-NK cells, and percentages of circulating human NK
cells were monitored in peripheral blood collected at 1, 7 and
14 days later. Here, NSG mice were given intermittent injections
of IL-15, thereby reducing the IL-15 support compared to the first
experiment. Consistent with previous observations, human NK
cells were almost absent at day 7 in mice co-treated with PBS. In
contrast, mice co-injected with IL-15 displayed stable levels of NK
cells from day 1 to day 7, which even increased in 4 out 5 mice at
day 14 (Figure 5A). In addition, significant percentages of UCB-
NK cells were identified in spleen and BM by day 14 (Figure 5B).
Moreover, examination of the NK cell phenotype in these tissues
revealed high expression level of CD16 and KIR receptors, which
were strongly increased compared to the infused UCB-NK cell
product (Figure 5C). All together, these data demonstrate that low
dose IL-15 mediates efficient UCB-NK cell survival and expansion
in vivo, and that further differentiation of UCB-NK cell products
occurs rapidly following adoptive transfer.
Adoptive Transfer of UCB-NK Cells Inhibits Growth of BM-
residing Human Leukemia Cells in Mice
Finally, to evaluate the cytolytic activity of UCB-NK cells in vivo,
we developed a leukemia xenograft model by injecting adult NSG
mice with leukemia cells intra-femorally (i.f.), therefore requiring
BM homing by infused UCB-NK cells to achieve anti-leukemic
response. For this, we used K562 leukemia cells expressing
Figure 4. Organ-distribution of UCB-NK cells following adoptive transfer. (A) For optimization of NK cell labelling procedure, increasing
number of UCB-NK cells were incubated with 2MBq 111In. Graphs show mean6 SD of three experiments performed each with a different UCB donor.
Good labelling efficiency and cell recovery were achieved using .46106 cells per 2 MBq. Subsequently (panels B-D), 0.4MBq 111In was added per
106 UCB-NK cells to label. (B) The capacity of 111In-NK cells to migrate in response to the chemokine CXCL12 was evaluated in vitro and compared to
that of unlabeled UCB-NK cells. The same experimental procedure was employed to assess the transwell migration of unlabeled and 111In-NK cells as
described in materials and methods, except that the proportion of 111In-labeled cells present in bottom chambers were quantified using a shielded 3-
inch-well-type gamma counter (Wizard; Pharmacia LKB). (C) Biodistribution analysis of 111In-NK cells 24 h after i.v. infusion, expressed as a percentage
of injected activity per gram of tissue of interest or per organ. Combined results from two experiments expressed as mean 6 SD (n = 6) are shown.
*Extrapolated values according to physiological parameters. (D) Representative 2D-reconstruction analysis of SPECT-CT illustrating the accumulation
of 111In-NK cells (orange) in bones (grey).
doi:10.1371/journal.pone.0064384.g004
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Luciferase (K562.LucGFP cells) to allow longitudinal monitoring
of tumor growth in living animals by bioluminescence imaging
(BLI). In this model, mice received a single infusion of UCB-NK
cells the day after K562.LucGFP cell i.f. injection, in combination
with low dose supportive IL-15 (Figure 6A). A dose of 206106 NK
cells per mouse was defined based on biodistribution studies to
approach an effector to target ratio of 1:1 in vivo. The anti-
leukemic potential of UCB-NK cells to target K562.LucGFP cells
was evaluated in two independent experiments with similar
outcomes (Figure 6B). Comparable K562 cell engraftment was
observed in both experiments and all control mice treated with
PBS and IL-15 except one displayed detectable i.f. tumors by day
15 (Figure 6B–C). In striking contrast, 8 out of 12 mice treated
with UCB-NK cells had undetectable tumor load by day 15.
Significant inhibition of K562.LucGFP cell progression following
UCB-NK cells infusion was demonstrated by BLI in time
(Figure 6D). Most importantly, a single infusion of ex vivo-
generated UCB-NK cells in combination with low-dose IL-15
prolonged survival of K562 i.f. injected mice of which 25% showed
long-term protection (Figure 6E–F). These results demonstrate
that UCB-NK cells are functional following adoptive transfer, and
that they are able to target and eliminate BM-residing leukemia
cells in vivo.
Discussion
To date, it is well established that NK cells mediate efficient
graft-versus-leukemia reactivity with improved control of relapse
in AML patients following alloSCT. This raises the interest in
exploiting NK cells for adoptive immunotherapy, particularly as
an adjuvant treatment approach to chemotherapy for elderly,
high-risk and refractory AML patients. Most trials reported so far
employed peripheral blood derived-NK cells enriched by CD3
depletion with or without CD56 selection from donor apheresis
products, and showed that enriched NK cell infusions are well
tolerated, without induction of GVHD or severe toxicity [9–
11,18]. Nevertheless, the clinical impact of NK cell-based therapy
remains inconsistent and several issues need to be optimized to
achieve clinical efficacy. In addition to conditioning regimens that
prevent rapid graft rejection and supply of exogenous cytokines
Figure 5. Low-dose IL-15 mediates efficient UCB-NK cell survival and expansion in vivo. Adult NSG mice were injected i.v. with 56106
UCB-NK cells with or without supportive IL-15. Recombinant human IL-15 was administered every 2–3 days for 2 weeks at the dose of 0.5 mg/mouse/
injection, starting the day of UCB-NK cell infusion. (A) Percentages of circulating human CD45+ cells in all CD45+ cells were quantified by flow
cytometry at the indicated time points. Each line corresponds to one mouse. (B) Percentages of human CD45+ cells in all CD45+ cells quantified in
spleen and bone marrow (leg bones) 2 weeks after UCB-NK cell infusion. (C) Expression of CD16 and CD158a/h,b,e on UCB-NK cells before and 2
weeks after infusion into NSG mice. Percentages were determined on human CD45+CD56+ NK cells isolated from spleen and bone marrow. Graphs
show the mean 6 SD of 5 mice.
doi:10.1371/journal.pone.0064384.g005
HSC-Derived NK Cells for AML Immunotherapy
PLOS ONE | www.plosone.org 8 June 2013 | Volume 8 | Issue 6 | e64384
Figure 6. A single infusion of UCB-NK cells inhibits growth of BM-residing human leukemia cells. The potential of UCB-NK cells to attack
human leukemia in vivo was evaluated in NSG mice bearing K562 intra-femoral (i.f.) tumors. (A) Experimental study design: adult NSG mice were
injected in their right femur with 105 K562.LucGFP cells. The day after, mice were treated with 206106 UCB-NK cells i.v. in combination with IL-15
administration (0.5 mg/mouse i.p. every 2–3 days for 14 days), or received PBS or IL-15 alone as control (n = 6 per group). Tumor load was monitored
by BLI from day 8 after K562.LucGFP cell inoculation and next every 3–4 days for 2 weeks. At later time points, only mice with undetectable tumor
load were imaged. (B) Two independent anti-leukemic studies were performed with similar outcomes. Tumor load per mouse measured at day 15
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like IL-2 supporting NK cell survival upon adoptive transfer, the
purity, the activation and the number of cells that can be infused
in patients are critical factors determining clinical response [9,11].
Since, new methodologies are currently emerging to generate
higher numbers of activated NK cells, including in vitro expansion
of donor-derived NK cells before infusion [19], as well as NK cell
generation from CD34+ hematopoietic stem/progenitor cells
[12,20,21]. In particular, the availability of cryo-preserved UCB
units and the development of GMP-compliant culture systems
constitute a very attractive approach to exploit the potential of NK
cell-based adoptive immunotherapy, with generation of a clinically
relevant dosages of UCB-NK cells with high purity and cytolytic
activity in vitro [13].
The present study was designed to pre-clinically evaluate the
in vivo anti-leukemic potential of UCB-NK cells generated with our
GMP-compliant culture system. To this end, we developed a
mouse model in which human K562.LucGFP leukemia cells are
directly implanted into the femur of NSG mice, thus requiring
BM-specific homing of infused UCB-NK cells to achieve anti-
tumor response. In this model, we showed that treatment with
UCB-NK cells in combination with supportive IL-15 potently
inhibited progression of K562 cells, thereby demonstrating that
UCB-NK cells are functional in vivo and have the capacity to
target leukemia cells within BM upon adoptive transfer. Impor-
tantly, prolongation of mice survival including complete and
persistent response in 25% of the mice was achieved following a
single infusion of UCB-NK cells and in the presence of low dose
IL-15 support. Considering that complete protection against K562
cells in vivo was mostly reported following multiple NK cell
infusions and/or prolonged high-dose IL-2 administration [21–
24], we believe that our results nicely illustrates the therapeutic
potential of UCB-NK cells in the clinic. In addition, biodistribu-
tion analysis showed that a relatively small proportion of our
current UCB-NK cell product accumulates in one femur within
24 h (,0.3% of 206106 cells, i.e. ,16105 UCB-NK cells per
femur), suggesting that inhibition of leukemia cell growth primarily
happened at a low effector to target ratio what also illustrates the
high cytolytic potential of ex vivo generated UCB-NK cells.
Our phenotypical analysis and in vitro migration studies support
that UCB-NK cells can actively home to BM following adoptive
transfer. Consistent expression of the chemokine receptor CXCR4
was detected on UCB-NK cells at the end of the culture process,
and robust migration in response to its ligand CXCL12 was shown
in vitro. Implication of the CXCR4/CXCL12 axis in regulating the
migration of human T and NK cells to BM has been reported in
several studies [25,26], including in human metastatic prostate
cancer [27]. Therefore, it is likely that UCB-NK cell homing to
BM is CXCR4/CXCL12-dependent. Nevertheless, we also
showed that UCB-NK cells display high expression of CXCR3
and CCR6, two receptors that could also regulate UCB-NK cell
trafficking to inflamed tissues in vivo. Future studies are now
warranted to demonstrate the role of the CXCR4/CXCL12 axis
in UCB-NK cell homing to BM and to examine its implication in
patients among other inflammatory pathways like CXCR3/
CXCL10–11. Also, trafficking of adoptively transferred NK cells
has not been addressed in leukemia patients yet. Use of 111In for
in vivo tracking of adoptively transferred NK cells has already been
reported in patients with renal cell carcinoma and liver metastases
[28,29], and at the pre-clinical level in xenograft mouse models of
leukemia [23]. Similar to our findings, early distribution of NK
cells in the lungs, and later in the liver, spleen and eventually BM
was visualized following systemic infusion. However, detailed
organ distribution of NK cells as well as demonstration of the
specificity of the visualized signal, particularly in BM, were not
available. Here, we showed that 111In-based NK cell tracking
provides good specificity and sensitivity, and will constitute a useful
method to study and correlate effective BM targeting with clinical
response in patients.
We reported previously that UCB-NK cells generated with our
GMP-compliant culture system display a relatively low expression
level of CD16 and KIRs at the end of the culture process [12].
However, we observed that the proportions of UCB-NK cells
expressing these markers were strongly increased two weeks after
adoptive transfer, indicating that UCB-NK cells can further
differentiate in vivo into a more mature cell population. These data
are in agreement with Huntington et al. who showed that rapid
IL-15 driven-transition of human CD56hiCD162KIR2 to
CD56dimCD16+KIR+ NK cells occurs in vivo [30]. Since KIR-
ligand mismatch triggers NK cell alloreactivity towards AML,
such phenotypic modifications might have important implications
in patients. In that view, UCB-NK cell reactivity towards AML
in vivo should be further addressed using HLA-expressing AML
cells in our i.f. NSG model.
In conclusion, our results strongly support that UCB-NK cells
constitute promising immunotherapeutic products to improve the
treatment of AML, as demonstrated by their capability to migrate
to BM and to inhibit progression of human leukemia cells
following adoptive transfer. In addition, we demonstrated efficient
UCB-NK survival in vivo in the presence of low dose human IL-15.
Transient elevation of IL-15 plasma levels was reported in AML
patients following immunosuppressive Cy/Flu conditioning [9,10],
what could favor in vivo expansion and maturation of UCB-NK
cells as well as clinical responses following UCB-NK cell adoptive
transfer. Since BM is the primary site of AML development and
encloses niches essential for leukemic stem cells causing relapse
[31], we believe that BM targeting is essential for elimination of
minimal residual disease and induction of optimal and persistent
clinical responses against AML. Strategies that aim at increasing
BM-specific chemokine receptors, like CXCR4, on UCB-NK cells
are now considered to enhance BM targeting. In addition, the
methodologies that we report here for UCB-NK cell tracking and
anti-leukemic effect monitoring will be instrumental to validate
future findings and to fully exploit the potential of UCB-NK cells
against AML and other hematological malignancies.
Supporting Information
Figure S1 The biodistribution of 111In-NK cells upon
adoptive transfer is reproducible between animals and
independent of the dose of injected cells. Five adult NSG
mice (mice M1 to M5) were infused i.v. with increasing number of
111In-NK cells (1MBq per 106 cells) and euthanized the day after
for organ collection and biodistribution analysis. For comparison,
proportions of activity quantified per gram of tissue of interest
were normalized to blood.
(TIF)
following K562.LucGFP cell IF injection from experiment 1 (black circles) and 2 (open circles). (C) BLI pictures acquired at day 15 after tumor cell i.f.
injection, and (D) tumor load in time (mean 6 SD, n = 6 per group). **p,0.01 UCB-NK cells+IL-15 vs. PBS and IL-15. Data of experiment 2 are shown.
(E) Time to first tumor detection by BLI and (F) mice survival analysed according to Mantel Cox test. One mouse from the IL-15 group (experiment 1)
died at day 19 after luciferine injection and was excluded from the survival analysis.
doi:10.1371/journal.pone.0064384.g006
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Figure S2 Low-dose IL-15 mediates efficient UCB-NK
cell survival and expansion in vivo. Adult NSG mice were
injected i.v. with 106106 UCB-NK cells with or without
supportive IL-15. Recombinant human IL-15 was administered
daily for 2 weeks at the dose of 0.5 mg/mouse/injection, starting
the day of UCB-NK cell infusion. Human NK cells were
quantified weekly in peripheral blood by flow cytometric analysis.
(A) Percentage of human CD45+CD56+ cells in blood of mice
injected with UCB-NK cells alone (dotted line, n = 5) or UCB-NK
cells with IL-15 (straight line, n= 6) over time. (B) Representative
dot-plots obtained 2 weeks after UCB-NK cell infusion.
(TIF)
Acknowledgments
We thank Rob Woestenenk (RUNMC, Nijmegen) for technical support in
flow cytometry. We also thank Bertien Dethmers-Ausema (University
Medical Center Groningen, The Netherlands) for training of the intra-
femoral injection in mice, as well as the bio-technicians from the RUNMC
animal facility for technical assistance.
Author Contributions
Conceived and designed the experiments: JC BH JDV OB RVDV JS HD.
Performed the experiments: JC AVDW. Analyzed the data: JC.
Contributed reagents/materials/analysis tools: MT GF JDV OB JS.
Wrote the paper: JC HD. Revised the manuscript: AVDW JDV OB NS JS.
References
1. Rowe JM (2009) Closer to the truth in AML. Blood 113: 4129–4130.
2. Estey E, Dohner H (2006) Acute myeloid leukaemia. Lancet 368: 1894–1907.
3. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin
60: 277–300.
4. Buchner T, Berdel WE, Wormann B, Schoch C, Haferlach T, et al. (2005)
Treatment of older patients with AML. Crit Rev Oncol Hematol 56: 247–259.
5. Lowenberg B, Downing JR, Burnett A (1999) Acute myeloid leukemia.
N Engl J Med 341: 1051–1062.
6. Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S (2008) Functions of
natural killer cells. Nat Immunol 9: 503–510.
7. Caligiuri MA (2008) Human natural killer cells. Blood 112: 461–469.
8. Ruggeri L, Mancusi A, Capanni M, Urbani E, Carotti A, et al. (2007) Donor
natural killer cell allorecognition of missing self in haploidentical hematopoietic
transplantation for acute myeloid leukemia: challenging its predictive value.
Blood 110: 433–440.
9. Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, et al.
(2005) Successful adoptive transfer and in vivo expansion of human haploiden-
tical NK cells in patients with cancer. Blood 105: 3051–3057.
10. Curti A, Ruggeri L, D’Addio A, Bontadini A, Dan E, et al. (2011) Successful
transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells
after infusion in elderly high risk acute myeloid leukemia patients. Blood 118:
3273–3279.
11. Rubnitz JE, Inaba H, Ribeiro RC, Pounds S, Rooney B, et al. (2010) NKAML:
a pilot study to determine the safety and feasibility of haploidentical natural killer
cell transplantation in childhood acute myeloid leukemia. J Clin Oncol 28: 955–
959.
12. Spanholtz J, Tordoir M, Eissens D, Preijers F, van der Meer A, et al. (2010)
High log-scale expansion of functional human natural killer cells from umbilical
cord blood CD34-positive cells for adoptive cancer immunotherapy. PLoS One
5: e9221.
13. Spanholtz J, Preijers F, Tordoir M, Trilsbeek C, Paardekooper J, et al. (2011)
Clinical-grade generation of active NK cells from cord blood hematopoietic
progenitor cells for immunotherapy using a closed-system culture process. PLoS
One 6: e20740.
14. Boggs DR (1984) The total marrow mass of the mouse: a simplified method of
measurement. Am J Hematol 16: 277–286.
15. Lehmann D, Spanholtz J, Osl M, Tordoir M, Lipnik K, et al. (2012) Ex vivo
generated natural killer cells acquire typical natural killer receptors and display a
cytotoxic gene expression profile similar to peripheral blood natural killer cells.
Stem Cells Dev 21: 2926–2938.
16. Campbell JJ, Qin S, Unutmaz D, Soler D, Murphy KE, et al. (2001) Unique
subpopulations of CD56+ NK and NK-T peripheral blood lymphocytes
identified by chemokine receptor expression repertoire. J Immunol 166: 6477–
6482.
17. Berahovich RD, Lai NL, Wei Z, Lanier LL, Schall TJ (2006) Evidence for NK
cell subsets based on chemokine receptor expression. J Immunol 177: 7833–
7840.
18. Nguyen S, Beziat V, Norol F, Uzunov M, Trebeden-Negre H, et al. (2011)
Infusion of allogeneic natural killer cells in a patient with acute myeloid leukemia
in relapse after haploidentical hematopoietic stem cell transplantation.
Transfusion 51: 1769–1778.
19. Tanaka J, Sugita J, Shiratori S, Shigematu A, Asanuma S, et al. (2012)
Expansion of NK cells from cord blood with antileukemic activity using GMP-
compliant substances without feeder cells. Leukemia 26: 1149–1152.
20. Yoon SR, Lee YS, Yang SH, Ahn KH, Lee JH, et al. (2010) Generation of
donor natural killer cells from CD34(+) progenitor cells and subsequent infusion
after HLA-mismatched allogeneic hematopoietic cell transplantation: a feasibil-
ity study. Bone Marrow Transplant 45: 1038–1046.
21. Woll PS, Grzywacz B, Tian X, Marcus RK, Knorr DA, et al. (2009) Human
embryonic stem cells differentiate into a homogeneous population of natural
killer cells with potent in vivo antitumor activity. Blood 113: 6094–6101.
22. Ayello J, van de Ven C, Fortino W, Wade-Harris C, Satwani P, et al. (2006)
Characterization of cord blood natural killer and lymphokine activated killer
lymphocytes following ex vivo cellular engineering. Biol Blood Marrow
Transplant 12: 608–622.
23. Guimaraes F, Guven H, Donati D, Christensson B, Ljunggren HG, et al. (2006)
Evaluation of ex vivo expanded human NK cells on antileukemia activity in
SCID-beige mice. Leukemia 20: 833–839.
24. Fujisaki H, Kakuda H, Shimasaki N, Imai C, Ma J, et al. (2009) Expansion of
highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res
69: 4010–4017.
25. Beider K, Nagler A, Wald O, Franitza S, Dagan-Berger M, et al. (2003)
Involvement of CXCR4 and IL-2 in the homing and retention of human NK
and NK T cells to the bone marrow and spleen of NOD/SCID mice. Blood 102:
1951–1958.
26. Pinthus JH, Waks T, Malina V, Kaufman-Francis K, Harmelin A, et al. (2004)
Adoptive immunotherapy of prostate cancer bone lesions using redirected
effector lymphocytes. J Clin Invest 114: 1774–1781.
27. Zhao E, Wang L, Dai J, Kryczek I, Wei S, et al. (2012) Regulatory T cells in the
bone marrow microenvironment in patients with prostate cancer. Oncoimmu-
nology 1: 152–161.
28. Brand JM, Meller B, Von Hof K, Luhm J, Bahre M, et al. (2004) Kinetics and
organ distribution of allogeneic natural killer lymphocytes transfused into
patients suffering from renal cell carcinoma. Stem Cells Dev 13: 307–314.
29. Matera L, Galetto A, Bello M, Baiocco C, Chiappino I, et al. (2006) In vivo
migration of labeled autologous natural killer cells to liver metastases in patients
with colon carcinoma. J Transl Med 4: 49.
30. Huntington ND, Legrand N, Alves NL, Jaron B, Weijer K, et al. (2009) IL-15
trans-presentation promotes human NK cell development and differentiation
in vivo. J Exp Med 206: 25–34.
31. Ishikawa F, Yoshida S, Saito Y, Hijikata A, Kitamura H, et al. (2007)
Chemotherapy-resistant human AML stem cells home to and engraft within the
bone-marrow endosteal region. Nat Biotechnol 25: 1315–1321.
HSC-Derived NK Cells for AML Immunotherapy
PLOS ONE | www.plosone.org 11 June 2013 | Volume 8 | Issue 6 | e64384
